2024-515786-34-02
Not yet recruiting
Phase 1
A Positron Emission Tomography (PET) study to examine the properties of a novel radioligand's suitability for imaging mutant huntingtin
CHDI Foundation Inc.1 site in 1 country27 target enrollmentStarted: December 17, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- CHDI Foundation Inc.
- Enrollment
- 27
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Prof Wim Vandenberghe
Scientific
CHDI Foundation Inc.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A positron emission tomography (PET) study to assess where the radiotracer [11C]AZ14132516 goes in the body following administration to healthy participants2022-502843-36-00AstraZeneca AB, AstraZeneca AB9
Completed
Not Applicable
Positron emission tomography (PET) measurement of the displaceability of [11C]FLB 457 from extra-striatal dopamine D2 receptors in maISRCTN23418225Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)16
Withdrawn
Phase 1
An imaging study of 64Cu-SARTATE using positron emission tomography in paediatric patients with high-risk neuroblastoma.ACTRN12617001259336Clarity Pharmaceuticals LTD10
Recruiting
Not Applicable
Positron emission computed tomography (PET) with L-[11C] methioninemalignant tumorJPRN-UMIN000010237Yamaguchi University School of Medicine300
Not yet recruiting
Not Applicable
Positron Emission Tomography (PET) imaging of neurodegenerative biomarkers in people ‘at risk’ for dementiaSubjective memory complaintsmild cognitive impairmentDementiaNeurological - DementiasNeurological - Neurodegenerative diseasesACTRN12622000274774The University of Sydney82